IL-33 Inhibitor Shows Reduced Exacerbations in COPD Trial
Source Summary
A first-in-class biologic targeting interleukin-33 (IL-33) demonstrated reduced exacerbations in people with COPD across a broad population of current and former smokers in double-blind trials. The results represent a new therapeutic approach for managing chronic obstructive pulmonary disease.
Why it matters
A new IL-33-targeting biologic offers a potential treatment option for COPD patients seeking to reduce disease exacerbations.
